Bliss GVS Pharma Share Price

Among India’s established pharmaceutical formulations exporters, Bliss GVS Pharma Limited has built a four-decade presence across suppositories, pessaries, capsules, tablets, syrups, and a broad range of other healthcare products – serving customers across more than sixty countries as of FY 2024-25. Bliss GVS Pharma Limited is the only EU-GMP (European Union – Good Manufacturing Practice) certified suppositories manufacturer in India.

Bliss GVS Pharma share price has historically tracked India’s pharmaceutical export cycles – moving with branded formulation demand, regulated market approvals, and African healthcare spending patterns. Investors monitoring the specialty pharma space often reference Bliss GVS Pharma stock price as a read on emerging market pharmaceutical demand and export-linked earnings momentum. Bliss GVS Pharma share trend has reflected the company’s evolving positioning from a niche dosage form manufacturer toward a diversified pharmaceutical formulations exporter.

Bliss GVS Pharma share price 2025-2026 has implied growing investor attention on its branded generics expansion and contract manufacturing capabilities. Bliss GVS Pharma stock price live has tracked sectoral sentiment across pharmaceuticals, healthcare exports, and regulated market approvals. Bliss GVS Pharma share price today has remained a reference point for participants monitoring India’s specialty pharmaceutical and healthcare exports sector.

Bliss GVS Pharma Share 2025-2026 may be monitored by investors assessing developments in the pharmaceutical manufacturing and specialty formulation segment. Bliss GVS Pharma live share price is often tracked by market participants to observe trading activity and investor sentiment toward companies operating in the pharmaceutical sector.

Bliss GVS Pharma Limited Fundamentals

(A) Company Background

Bliss GVS Pharma company history begins in 1984, when the company was incorporated as Bliss Chemicals and Pharmaceuticals India Private Limited in Mumbai, Maharashtra. Bliss GVS Pharma headquarters is at 102, Hyde Park, Sakivihar Road, Andheri East, Mumbai. Bliss GVS Pharma Limited expansion has continued through the addition of wholly-owned subsidiaries across Africa, Europe, and the UK, alongside investment in a new multi-product manufacturing facility in Palghar, Maharashtra. Bliss GVS Pharma share price has reflected this expanding international and manufacturing footprint across successive fiscal cycles.

(B) Company Product Lines

Bliss GVS Pharma Limited product line spans two primary categories serving institutional, retail, and contract manufacturing clients across more than sixty countries as of FY 2024-25:

1. Pharma Products: The flagship segment – covering Suppositories, Pessaries, Capsules, Soft Gelatin Capsules, Tablets, Effervescent Tablets, Syrups, Dry Powder for Injection, Dry Powder for Oral Suspension, Parenterals, Injections, Oral Solids, Lozenges, Sachets, Eye and Ear Drops, Nasal Solutions, Lotions, Creams, Gels, Ointments, Topical Preparations, Transdermal Patches, and Liquid Preparations. Bliss GVS Pharma Limited business segments in pharma products span anti-malarial, anti-fungal, anti-bacterial, anti-inflammatory, antibiotic, contraceptive, and anti-diabetic therapeutic areas.
2. Other Healthcare Products: Bliss GVS Pharma Limited key offerings in this segment include Balms, Nasal Inhalers, OTC (Over-the-Counter) Products, Petroleum Jellies, Roll-ons, Shampoos, Soaps, Sprays, Lotions, and Vaginal Washes – completing the Bliss GVS Pharma Limited value chain across pharmaceutical and consumer healthcare segments. Bliss GVS Pharma Limited customers span institutional buyers, branded generics distributors, and contract manufacturing clients across Africa, Europe, Southeast Asia, and the Americas.

(C) Bliss GVS Pharma Company Revenue Model

The Bliss GVS Pharma Limited business model operates across pharmaceutical formulations exports, domestic branded generics sales, and contract research and manufacturing services – with exports contributing the largest revenue share as of FY 2024-25. Bliss GVS Pharma Limited revenue streams draw from both high-margin branded generic formulations and volume-driven contract manufacturing, creating a naturally balanced mix. Branded formulation demand cycles and African healthcare spending patterns are factors that Bliss GVS Pharma share price has historically responded to across reporting periods. Regulatory approval timelines and raw material procurement cycles are variables that Bliss GVS Pharma stock price has consistently mirrored across quarterly and annual results.

(D) Bliss GVS Pharma Geographic Presence

Bliss GVS Pharma Limited geographic presence combines a Mumbai-rooted corporate headquarters with a Maharashtra-led manufacturing base and a broad international export footprint as of FY 2024-25.

• Headquarters / Registered and Corporate Office: Andheri East, Mumbai, Maharashtra
• India Footprint:
  • Mumbai (corporate headquarters)
  • Palghar, Maharashtra (manufacturing facilities – Aliyali and Vevoor plants)
• International Presence: Exports to more than sixty countries across Africa, Europe, Southeast Asia, and the Americas; wholly owned subsidiaries in Nigeria, Tanzania, Kenya, Ethiopia, and the UK. Bliss GVS Pharma share price has reflected export market expansion and international subsidiary performance as of FY 2024-25.

(E) Leadership

A snapshot of Bliss GVS Pharma Limited leadership / Bliss GVS Pharma Limited board of directors as of FY 2024-25:

• SN Kamath— Managing Director
• Santosh Parab— Independent Director
• Shilpa Bhatia— Independent Director
• Nandkumar Kashinath Chodankar – Chairman & Independent Director

Bliss GVS Pharma Limited management draws on sectoral expertise across pharmaceutical manufacturing, international marketing, regulatory affairs, and finance. Bliss GVS Pharma Limited corporate governance remains aligned with SEBI (Securities and Exchange Board of India) LODR (Listing Obligations and Disclosure Requirements) regulations.

(F) Key Milestones

• 1984: Incorporated as Bliss Chemicals and Pharmaceuticals India Private Limited in Mumbai
• 1985: Commenced business operations; began manufacture of pharmaceutical formulations
• 2010: Listed on BSE and NSE on July 26, 2010; Bliss GVS Pharma share price has entered public market discovery at listing
• 2015: Established Asterisk Lifesciences Limited as a wholly-owned foreign subsidiary in the UK for European registrations and marketing
• 2018: Bliss GVS Pharma divested Lifeon Labs Private Limited along with other subsidiaries to focus on core pharmaceutical operations.
• 2019: Invested in Lifeon Labs Private Limited; expanded wholly-owned subsidiary network across Africa
• 2024: Commissioned expanded manufacturing capacity at Palghar; progressed EU-GMP recertification cycle. Bliss GVS Pharma stock price has reflected this manufacturing expansion as of FY 2024-25

(G) Industry Perspective

India’s pharmaceutical formulations export sector has been shaped by decades of generics-led global demand, with structural acceleration driven by African healthcare infrastructure investment, WHO (World Health Organization) prequalification frameworks, and regulated market generic approvals as of FY 2024-25. Suppositories and pessaries represent a specialised dosage segment globally, where EU-GMP certification creates high entry barriers and limited competition for incumbents. Anti-malarial, anti-fungal, and anti-inflammatory branded generic demand in Sub-Saharan Africa has grown steadily, driven by rising healthcare budgets, institutional procurement through government tenders, and expanding private healthcare networks. Globally, the contract pharmaceutical manufacturing sector has been growing at a meaningful pace, as innovator companies increasingly outsource specialised dosage form production. Regulatory harmonisation across African markets and expanded WHO prequalification lists have created new addressable markets for Indian pharma exporters with established compliance frameworks. Bliss GVS Pharma share price has tended to move with these export demand cycles. Bliss GVS Pharma stock price has historically reflected African market dynamics and EU-GMP certification milestones across reporting periods.

Bliss GVS Pharma Stock Market Presence – Listing And Index Representation

Bliss GVS Pharma Limited has been listed on both the Bombay Stock Exchange (BSE) – code 506197 – and the National Stock Exchange (NSE) – ticker BLISSGVS – since July 26, 2010. Its International Securities Identification Number (ISIN) is INE416D01022. Bliss GVS Pharma share price has drawn participation from domestic institutional investors, high-net-worth individuals, and retail participants – with liquidity consistent with a small-cap pharmaceutical name. The stock sits outside headline indices like Nifty 50 and Sensex but finds tracking within BSE Healthcare and pharma export baskets. Regular Bliss GVS Pharma earnings filings give market participants visibility across export formulation revenues and subsidiary performance. Bliss GVS Pharma stock price has remained sensitive to African tender announcements and EU-GMP certification outcomes. Bliss GVS Pharma live price remains accessible across NSE, BSE, and financial data platforms.

Bliss GVS Pharma Stock Performance And Share Price History

Bliss GVS Pharma share price history from FY 2020-21 to FY 2024-25 captures a journey from pandemic-era disruption through export recovery and branded generics re-rating phases. The five-year qualitative CAGR from FY 2020-21 to FY 2024-25 reflects navigation of African market volatility and raw material cost cycles. Across the three-year window from FY 2022-23 to FY 2024-25, Bliss GVS Pharma stock price has moved with pharmaceutical export sector sentiment and domestic healthcare spending. The one-year FY 2024-25 qualitative CAGR reflects export volume recovery and margin improvement. Bliss GVS Pharma share price history has traversed periods of consolidation and sharp re-rating around EU-GMP and WHO prequalification milestones. Bliss GVS Pharma investor sentiment has swung between conviction on export recovery and caution on African tender concentration. Bliss GVS Pharma volatility has stayed elevated, with event-driven moves around quarterly results and regulatory announcements.

Bliss GVS Pharma Investor Relevance And Role In Portfolio

Africa’s expanding healthcare budgets and India’s pharmaceutical export policy tailwinds anchor the Bliss GVS Pharma Limited investment thesis for long-term investors. Tender concentration in African markets and regulatory approval cycles mean Bliss GVS Pharma share price has shown sharp, event-driven movements during key procurement and certification periods. EU-GMP recertification and contract manufacturing expansion continue shaping Bliss GVS Pharma long-term outlook as of FY 2024-25. Portfolio evaluators tracking Bliss GVS Pharma fundamentals weigh its suppositories and pessaries market leadership against export revenue concentration. Bliss GVS Pharma P/E ratio (Price-to-Earnings ratio) has compressed during tender delays and expanded during export recovery phases. Bliss GVS Pharma EPS (Earnings Per Share) has remained sensitive to African market demand and raw material pricing cycles. Consistent dividend payments alongside Bliss GVS Pharma performance in FY 2024-25 add an income dimension. Bliss GVS Pharma market cap places it in the small-cap pharmaceutical universe.

Bliss GVS Pharma Sectoral Relevance And Peer Positioning

Bliss GVS Pharma Limited peer comparison sits within India’s pharmaceutical formulations export segment, alongside Ipca Laboratories Limited, Alkem Laboratories Limited, JB Chemicals and Pharmaceuticals Limited, Suven Pharmaceuticals Limited, and Emami Limited. Bliss GVS Pharma market cap places it as a small-cap player – distinctly positioned against larger diversified pharma peers like Ipca and Alkem, yet differentiated through its suppositories and pessaries market leadership and exclusive EU-GMP certification. It is often compared against JB Chemicals and Suven Pharmaceuticals in the specialty dosage and export formulations space, and for India’s Africa-focused branded generics story. Bliss GVS Pharma Limited SWOT analysis highlights dosage form specialisation and regulatory certifications as core strengths, with African tender concentration and raw material volatility as primary challenges.

Bliss GVS Pharma Summary

Bliss GVS Pharma share price has continued to reflect India’s pharmaceutical export story – from suppositories and pessaries demand cycles to African healthcare expansion. Bliss GVS Pharma stock price has remained tied to export recovery trends and EU-GMP certification milestones. Built on four decades of pharmaceutical manufacturing heritage, the Bliss GVS Pharma Limited business model spans formulations exports, branded generics, and contract manufacturing.